0 patents currently held, every record listed here
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
This portfolio holds none of the 7 US patents in force on its record. from the record
Of the 7 now held by other companies, 7 name Roche Molecular Systems Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end
When these terms end
Each bar runs from grant to computed term end. 2020 to 2035.
US D900,835
Display Screen or Portion Thereof with Graphical User Interface for Oncology Progress for Multidiscilinary Cancer Treatment Planning
Nov 3, 2035
US D900,836
Display Screen or Portion Thereof with Graphical User Interface for Interactive Guidelines for Multidisciplinary Cancer Treatment Planning
Nov 3, 2035
US D900,837
Display Screen or Portion Thereof with Graphical User Interface for Literature Search Information for Multidisciplinary Cancer Treatment Planning
Nov 3, 2035
US D901,521
Display Screen or Portion Thereof with Graphical User Interface for Similar Patient Information for Multidisciplinary Cancer Treatment Planning
Nov 10, 2035
US D902,226
Display Screen or Portion Thereof with Graphical User Interface for Timeline Information for Multidisciplinary Cancer Treatment Planning
Nov 17, 2035
US D902,227
Display Screen or Portion Thereof with Graphical User Interface for Patient Information for Multidisciplinary Cancer Treatment Planning
Nov 17, 2035
US D902,228
Display Screen or Portion Thereof with Graphical User Interface for Clinical Information for Multidisciplinary Cancer Treatment Planning
Nov 17, 2035
20232026202920322035
Every computed term in this portfolio is shown above.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Nov 2035 · High confidence
The most cited patent in this portfolio, cited by 34 later US patents, top 25% of design patents granted in 2020 in our data. Protection runs to 2035.
now held by Roche Molecular Systems, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first.
Also on record: 7 patents in force now held by others. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.